{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T16:32:09Z","timestamp":1716309129545},"reference-count":9,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1547,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1111\/j.1753-5174.2011.00035.x","type":"journal-article","created":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T14:48:39Z","timestamp":1307458119000},"page":"33-41","source":"Crossref","is-referenced-by-count":10,"title":["Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial"],"prefix":"10.1111","volume":"4","author":[{"given":"Sergei A.","family":"Tjulandin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiner","family":"Els\u00e4sser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erich","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Buchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,6,7]]},"reference":[{"key":"10.1111\/j.1753-5174.2011.00035.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198701083160203","article-title":"Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial","volume":"316","author":"Eschbach","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1753-5174.2011.00035.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(86)92192-6","article-title":"Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis","volume":"2","author":"Winearls","year":"1986","journal-title":"Lancet"},{"key":"10.1111\/j.1753-5174.2011.00035.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response","volume":"86","author":"Cazzola","year":"1995","journal-title":"Blood"},{"key":"10.1111\/j.1753-5174.2011.00035.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2141.2003.04439.x","article-title":"Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production","volume":"122","author":"Cazzola","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1753-5174.2011.00035.x-BIB5|cit5","first-page":"1289","article-title":"Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy","volume":"10","author":"Granetto","year":"2003","journal-title":"Oncol Rep"},{"key":"10.1111\/j.1753-5174.2011.00035.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.ejca.2004.07.015","article-title":"EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer","volume":"40","author":"Bokemeyer","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1111\/j.1753-5174.2011.00035.x-BIB7|cit7","first-page":"13","article-title":"The functional assessment of cancer therapy-anaemia (FACT-AN) scale: A new tool for the assessment of outcomes in cancer anaemia and fatigue","volume":"34","author":"Cella","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1111\/j.1753-5174.2011.00035.x-BIB8|cit8","unstructured":"European Medicines Agency EMEA Public statement: European medicines agency starts review of the safety of epoetins 2007"},{"key":"10.1111\/j.1753-5174.2011.00035.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ncponc0451","article-title":"Cancer-related anemia and recombinant human erythropoietin-An updated overview","volume":"3","author":"Bohlius","year":"2006","journal-title":"Nature Clin Pract Oncol"}],"container-title":["Archives of Drug Information"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1753-5174.2011.00035.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1753-5174.2011.00035.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T10:04:16Z","timestamp":1625565856000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1753-5174.2011.00035.x"}},"subtitle":["Epoetin Theta and Nonplatinum Chemotherapy"],"short-title":[],"issued":{"date-parts":[[2011,6,7]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1753-5174.2011.00035.x","relation":{},"ISSN":["1753-5174"],"issn-type":[{"value":"1753-5174","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6,7]]}}}